Headache

SAN DIEGO —American Indians are less likely to receive a migraine diagnosis or migraine treatment compared with their white counterparts due to a variety of socioeconomic factors, according to a poster.

SAN DIEGO — Children and adolescents treated with fremanezumab experienced fewer migraine and headache days compared with placebo, according to an abstract presented at the American Academy of Neurology Annual Meeting.

SAN DIEGO — Facing a workforce shortage and higher patient volumes, neurologists are looking for ways to collaborate with primary care providers to improve outcomes, according to speakers at the American Academy of Neurology Annual Meeting.

People diagnosed with headache had a greater risk for attempting and completing suicide, according to results of a cohort study published in JAMA Neurology.

The ACP issued new clinical guidance on preventing episodic migraines, classified as one to 14 headache days per month, in nonpregnant or nonlactating adults in outpatient settings.

In three clinical trials, treatment with atogepant relieved migraine symptoms as soon as day 1, with consistent reductions through 4 weeks compared with placebo, according to research published in Neurology.

Headache is one of the most common complaints seen by health care providers. There are various types of primary headache disorders, with the most common being migraine, tension headache and cluster headache.

Affecting more than 1 billion people worldwide, migraine is among the most common neurological diseases. During their lives, 43% of women and 18% of men develop migraine.

Pregabalin and topiramate significantly reduced the frequency and intensity of migraines in children and adolescents, especially when combined with vitamin supplements, according to a meta-analysis published in JAMA Network Open.

Migraine is a complex neurological disease that disproportionately affects women during their most productive years.